top of page
A DAUNTLESS
APPROACH
LEVERAGING THE POWER OF ANTIBODIES
TO TREAT CANCERS OF UNMET NEED
WHO WE ARE
Dauntless Biotherapeutics is a private preclinical oncology company led and advised by an amazing team of researchers and industry veterans
WHAT WE'RE DOING
Conducting a seed round to raise capital to perform lead optimization, in vivo, and non-GLP toxicity studies in preparation of IND filing.
EXPLORE THE SCIENCE
We are developing an Antibody Drug Conjugate (ADC), to an undisclosed Tumor Associated Antigen (TAA), to treat cancers of unmet need.
OUR WEBSITE IS CURRENTLY IN DEVELOPMENT. STAY TUNED FOR ADDITIONAL CONTENT.
In the meantime, we'd love to hear from you!
LET'S
CONNECT
Whether you’re interested in partnering with us, investing in Dauntless Biotherapeutics, or inquiring about career opportunities, we’d be glad to hear from you.
STAY IN THE KNOW
bottom of page